Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BLRX

Bioline Rx Ltd ADR

Jan 17 • 04:00PM ET

0.1015

Dollar change -0.0204
Percentage change -16.74	%

Healthcare • Biotechnology • Israel • NASD

Peers: BPMC ARGX MGNX ONCY AFMD ADAP IMMP KPTI CTMX FATE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	0.56%	Shs Outstand	142.34M	Perf Week	-28.97%
Market Cap	14.45M	Forward P/E	-	EPS next Y	-0.08	Insider Trans	0.00%	Shs Float	141.55M	Perf Month	-52.57%
Income	-19.92M	PEG	-	EPS next Q	-0.02	Inst Own	2.35%	Short Float	0.58%	Perf Quarter	-78.40%
Sales	21.99M	P/S	0.66	EPS this Y	91.44%	Inst Trans	48.63%	Short Ratio	0.13	Perf Half Y	-87.15%
Book/sh	0.11	P/B	0.95	EPS next Y	-8.69%	ROA	-37.72%	Short Interest	0.82M	Perf Year	-92.59%
Cash/sh	0.20	P/C	0.50	EPS next 5Y	-	ROE	-184.09%	52W Range	0.10 - 1.44	Perf YTD	-52.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.53%	ROI	-71.70%	52W High	-92.95%	Beta	1.47
Dividend TTM	-	Quick Ratio	1.37	Sales past 5Y	0.00%	Gross Margin	65.79%	52W Low	2.53%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.52	EPS Y/Y TTM	68.50%	Oper. Margin	-126.62%	RSI (14)	28.66	Volatility	24.62% 17.73%
Employees	38	Debt/Eq	3.48	Sales Y/Y TTM	-	Profit Margin	-90.57%	Recom	1.00	Target Price	4.57
Option/Short	Yes / Yes	LT Debt/Eq	2.26	EPS Q/Q	71.90%	Payout	-	Rel Volume	3.95	Prev Close	0.12
Sales Surprise	-6.56%	EPS Surprise	100.00%	Sales Q/Q	-	Earnings	Nov 25 BMO	Avg Volume	6.50M	Price	0.10
SMA20	-44.43%	SMA50	-63.56%	SMA200	-81.52%	Trades		Volume	25,716,824	Change	-16.74%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-17	Upgrade	Maxim Group	Hold → Buy	$1 → $3
Feb-13-17	Initiated	Rodman & Renshaw	Buy	$3
Aug-12-16	Downgrade	Maxim Group	Buy → Hold	$4 → $1
Aug-17-15	Reiterated	Maxim Group	Buy	$8 → $4
Jul-27-15	Reiterated	ROTH Capital	Buy	$10.50 → $7
Jun-22-15	Initiated	JMP Securities	Mkt Outperform	$5

Jan-17-25 07:00AM	BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares (PR Newswire) -16.74%
Jan-06-25 08:57AM	BioLineRx Announces $10 Million Registered Direct Offering (PR Newswire) -40.87%
Dec-10-24 08:30AM	Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors (GlobeNewswire)
Nov-26-24 10:00AM	BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts (GuruFocus.com)
Nov-25-24 07:00AM	BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value (PR Newswire)
06:35AM	Loading…
Nov-22-24 06:35AM	BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell (TipRanks) -13.97%
Nov-21-24 06:30AM	BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd. (PR Newswire) -40.71%
Nov-20-24 07:19AM	BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 (PR Newswire)
Nov-05-24 09:00AM	BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 (PR Newswire)
Oct-16-24 07:00AM	BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide (PR Newswire) +7.40%
Sep-17-24 01:01PM	BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection (PR Newswire)
Aug-15-24 07:00AM	BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire) -12.48%
Aug-08-24 07:00AM	BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 (PR Newswire) +6.36%
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
07:00AM	Loading…
May-30-24 07:00AM	BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) (PR Newswire) +18.81%
May-29-24 08:03AM	BioLineRx Ltd. (NASDAQ:BLRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-28-24 11:53AM	BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
May-24-24 07:00AM	BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting (PR Newswire) +13.24%
May-22-24 07:00AM	BioLineRx to Report First Quarter 2024 Results on May 28, 2024 (PR Newswire)
May-17-24 05:00PM	BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
May-06-24 07:00AM	BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 (PR Newswire) +5.63%
Apr-17-24 07:00AM	BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting (PR Newswire)
Apr-10-24 07:00AM	BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement (PR Newswire)
Apr-01-24 09:00AM	BioLineRx Announces $6 Million Registered Direct Offering (PR Newswire) -23.20%
Mar-27-24 12:23PM	BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.77%
Mar-26-24 07:00AM	BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire) -20.77%
Mar-20-24 07:00AM	BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 (PR Newswire)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
07:00AM	Loading…
Mar-04-24 07:00AM	BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production (PR Newswire)
Feb-28-24 07:00AM	BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) (PR Newswire) +7.32%
Feb-25-24 02:12PM	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond (InvestorPlace)
Feb-16-24 07:00AM	BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® (PR Newswire) +13.12%
Dec-21-23 07:00AM	BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease (PR Newswire) +5.06%
Nov-21-23 03:45PM	BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -10.59%
Nov-20-23 07:00AM	BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Nov-13-23 07:00AM	BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 (PR Newswire)
Nov-02-23 03:12PM	3 Tech Stocks That Wall Street Loves More Than Nvidia (InvestorPlace)
Oct-31-23 09:00AM	BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures (PR Newswire) +12.78%
Oct-30-23 11:38AM	3 Top Penny Stocks to Make You a Millionaire in 5 Years (InvestorPlace)
Oct-12-23 07:00AM	BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment (PR Newswire)
Sep-28-23 07:00AM	BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) (PR Newswire)
Sep-19-23 07:00AM	BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer (PR Newswire) +11.44%
Sep-14-23 05:36AM	BLRX: Go! (Zacks) +6.02%
Sep-11-23 07:00AM	BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma (PR Newswire)
Sep-05-23 06:04AM	BLRX: On Your Marks, Get Set (Zacks) +21.29%
Aug-31-23 08:18AM	BioLineRx Ltd. (NASDAQ:BLRX) Q2 2023 Earnings Call Transcript (Insider Monkey) +25.90%
Aug-30-23 07:00AM	BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Aug-22-23 07:00AM	BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 (PR Newswire)
Aug-07-23 02:34PM	3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now (InvestorPlace)
Jul-18-23 03:22PM	3 Smart Penny Stocks with Huge Potential (InvestorPlace)
Jul-17-23 07:00AM	BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide (PR Newswire)
Jun-29-23 02:00PM	The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023 (InvestorPlace)
Jun-07-23 05:25AM	BLRX: First Quarter Results (Zacks Small Cap Research)
May-24-23 07:00AM	BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
May-17-23 07:00AM	BioLineRx to Report First Quarter 2023 Results on May 24, 2023 (PR Newswire) +11.11%
May-04-23 01:56PM	7 High-Potential Penny Stocks in the Biotech Sector (InvestorPlace)
Apr-25-23 07:00AM	BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Apr-17-23 11:00AM	BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma (PR Newswire)
Apr-04-23 08:21PM	The 3 Best Biotech Stocks Under $1 to Buy for April (InvestorPlace)
Mar-24-23 07:15AM	BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 11:42AM	BLRX: Confidence in a Strong Launch (Zacks Small Cap Research)
Mar-22-23 07:00AM	BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Mar-15-23 07:00AM	BioLineRx to Report 2022 Annual Financial Results on March 22, 2023 (PR Newswire)
Mar-06-23 07:00AM	BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease (PR Newswire)
Jan-04-23 07:00AM	BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer (PR Newswire) +6.72%
Dec-20-22 12:36PM	BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate (Benzinga)
07:00AM	BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors (PR Newswire)
Dec-05-22 04:00AM	BLRX: Self-Commercialization in the US (Zacks Small Cap Research)
Nov-28-22 04:30PM	BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event (PR Newswire)
Nov-15-22 07:00AM	BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Nov-10-22 04:30PM	BioLineRx to Report Third Quarter 2022 Results on November 15, 2022 (PR Newswire) -24.00% +6.67%
07:00AM	BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization (PR Newswire)
Nov-04-22 04:30PM	BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Nov-03-22 09:11AM	BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Nov-02-22 09:21AM	BLRX: Cast Off the Bowlines: Aphexda Commercialization (Zacks Small Cap Research)
Sep-27-22 07:00AM	BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization (PR Newswire)
Sep-19-22 08:00AM	BioLineRx Announces $15 Million Registered Direct Offering (PR Newswire) -33.77%
Sep-15-22 12:38PM	BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer (Benzinga)
07:00AM	BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital (PR Newswire)
Sep-12-22 07:00AM	BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization (PR Newswire) -9.89%
Aug-18-22 07:47AM	BLRX: September NDA (Zacks Small Cap Research)
Aug-16-22 07:00AM	BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) -6.28%
Aug-11-22 07:00AM	BioLineRx to Report Second Quarter 2022 Results on August 16, 2022 (PR Newswire)
Jun-29-22 08:00AM	BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures (PR Newswire) -5.38%
Jun-28-22 07:00AM	BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC) (PR Newswire)
Jun-16-22 07:00AM	BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer (PR Newswire)
May-12-22 10:16AM	BLRX: First Quarter 2022 Operational and Financial Results (Zacks Small Cap Research)
May-11-22 07:00AM	BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) -12.40%
May-05-22 07:00AM	BioLineRx to Report First Quarter 2022 Results on May 11, 2022 (PR Newswire)
Mar-17-22 08:55AM	BLRX: 2021 Results (Zacks Small Cap Research)
Mar-16-22 07:00AM	BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update (PR Newswire)
Mar-10-22 07:00AM	BioLineRx to Report 2021 Annual Results on March 16, 2022 (PR Newswire)
Mar-03-22 07:00AM	BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization (PR Newswire)
Jan-31-22 04:20AM	BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide (Zacks Small Cap Research) +5.20%
Jan-24-22 07:00AM	BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors (PR Newswire)
Jan-18-22 07:00AM	BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients (PR Newswire) +8.46%
Dec-17-21 07:00AM	BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (PR Newswire) +5.96%
Dec-15-21 07:00AM	BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) (PR Newswire)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLRX

Bioline Rx Ltd ADR

Upgrade your FINVIZ experience